[ad_1]
The European Medicines Agency (EMA) said it has established a possible link between Pfizer’s COVID-19 mRNA vaccines (PFE) and Moderna (MRNA) and rare inflammatory heart diseases like myocarditis and pericarditis, according to Reuters.
However, the EMA also commented that the known and potential benefits of all licensed COVID-19 vaccines outweigh their risks.
The regulator has examined more than 300 cases of heart disease in the European Economic Area (EEA) region, which includes the European Union, Iceland, Norway and Liechtenstein.
So far 177 million doses of Pfizer’s Comirnaty and 20 million doses of Moderna’s Spikevax vaccine had been administered as of May 31.
The EMA concluded that Pfizer’s Comirnaty vaccine was the cause of most cases of myocarditis and pericarditis. (See PFE stock charts on TipRanks)
The regulator said both heart conditions should be included in the side effects list of both vaccines. Shortness of breath, palpitations and chest pain are some of the symptoms associated with these conditions.
He added that these conditions occurred within 14 days of the date of vaccination, with a higher number of cases reported in younger men after the second dose.
After the results, Pfizer made a statement, saying the two reported conditions were “generally mild” and people “tend to recover quickly after standard treatment and rest.”
In addition, similar studies have been carried out on vaccines from Johnson & Johnson (JNJ) and AstraZeneca (AZN). However, no link has been found between these vaccines and similar heart conditions. The EMA has asked the two companies to provide more data for further analysis.
Meanwhile, the EMA has warned people with a history of the rare blood disease, Capillary Leak Syndrome (CLS), to refrain from getting a Johnson & Johnson vaccine after reviewing three cases of CLS, which occurred within two days of receiving the vaccine.
In June, the EMA added CLS as a possible side effect of AstraZeneca’s vaccines and advised people with similar pre-existing conditions not to get the shot.
The recent findings from the EMA could put pressure on the vaccinations of these companies in Europe in the future. The EMA Safety Panel has advised healthcare professionals to be aware of post-vaccine symptoms as it continues to monitor the safety of approved vaccines.
RBC Capital analyst Daniel Busby recently raised the price target on Pfizer from $ 43 to $ 44 (upside potential of 11.15) and reiterated a holding rating on the stock.
Overall, the stock has a consensus hold rating based on 1 buy, 9 takes and 1 sell. Pfizer’s average price target of $ 43.22 implies upside potential of 9.1% from current levels. PFE shares have jumped 19% in the past year.
Related News:
Why has Helen of Troy slipped 6% despite strong first quarter results?
MSC Industrial Reports Strong Third Quarter Results, Increases Savings Prospects
Freedom from Brunswick Corporation acquires the Spanish Fanautic Club
More recent articles from Smarter Analyst:
[ad_2]
Source link